Place an order request to the broker. The personal manager will contact you to confirm the order.

Order Summary

Asset: Select instrument
Quantity: -
Price per Unit: ? This price is indicative and shown for informational purposes only. The final execution price may change. -
Total Amount: -

Order Expiration

Order remains active until you cancel it or it gets filled

Order expires at the end of the selected day

Order Placed Successfully

Your order has been submitted! Our team will contact you shortly to confirm.

Order Type: -
Asset: -
Quantity: -
Total Amount: -
Manually record a past trade to keep your portfolio up to date. This helps track your P&L accurately.
Total Amount: $0.00

Trade Added Successfully

Trade recorded! Your portfolio data will be recalculated.

Type: -
Asset: -
Quantity: -
Price: -
Total: -

Chat Options

Web Search
Search the internet for recent information
Portfolio Context
Include your portfolio in the conversation
Market Data
Access real-time market information
Watchlist Context
Include your watchlist companies

Joby Aviation, Inc. (JOBY)

2026-09-01T14:09:17.335337+00:00

Executive Summary

Joby Aviation shares fell a further 10.53% since the August 19 report, closing at $6.71 and extending an uninterrupted four-report decline from $8.71 (August 7) to current levels — a cumulative drop of approximately 23% over three weeks. The move occurred without company-specific negative catalysts; instead, it coincided with an announced defense-sector acquisition (Resonant Sciences) that has yet to alter market sentiment, while a routine 8-K filing provided no offsetting financial detail. The technical and momentum picture continues to deteriorate, reinforcing a bearish near-term bias despite incremental long-term diversification news.

Key Updates

Since the last report, JOBY declined 10.53%, with a 1.90% drop on the most recent session and a 7.06% decline over five days, confirming the move is broad-based rather than driven by a single-day event. Two developments emerged during this period: (1) Cerberus Capital Management agreed to sell Resonant Sciences — a radar, navigation, and RF mission systems developer — to Joby, creating a dedicated defense business, though the transaction is not expected to close until H1 2027 and financial terms were undisclosed; and (2) Joby filed a Form 8-K disclosing results of operations, but without specific revenue, EPS, or other financial metrics in the filing notice itself. Neither disclosure appears to have provided the market with a clear reason to reverse the prevailing downtrend.

Current Trend

JOBY remains in a well-established downtrend, down 49.17% YTD and 33.30% over six months. The stock has breached each of its recent support levels in succession — $8.35, then $7.50, and now $6.71 — with each level subsequently acting as resistance. The pace of decline has been consistent across the past three reporting periods (-4.14%, -10.13%, -10.53%), indicating accelerating rather than stabilizing downside momentum. No clear reversal signal is evident in the price action to date.

Investment Thesis

The long-term thesis for Joby rests on successful FAA certification and commercialization of its eVTOL air taxi platform, supported by strategic partnerships and, increasingly, diversification into adjacent markets such as defense. The Resonant Sciences acquisition supports this diversification angle by adding a dedicated defense business built on radar, navigation, and RF mission systems — potentially reducing reliance on eVTOL certification timing alone. However, the thesis remains contingent on capital availability, execution against certification milestones, and market willingness to fund a pre-revenue growth story amid a prolonged share price decline.

Thesis Status

The thesis is under increasing pressure. While the Resonant acquisition is directionally consistent with a diversification narrative, its 2027 close date and undisclosed terms mean it offers no near-term financial support to the stock. Combined with an 8-K filing that lacked disclosed financial metrics, the market has been given limited fundamental data to reassess valuation, and the continued decline suggests investor confidence is eroding faster than new developments can offset. The risk profile has shifted further to the downside relative to the prior report.

Key Drivers

The primary driver behind the current move remains price-driven, with no fresh negative company-specific news identified. Relevant developments include:

  • The Cerberus/Resonant Sciences acquisition, which establishes a dedicated Joby defense business but will not close until H1 2027 and carries no disclosed financial terms.
  • The August 5 Form 8-K filing, which disclosed results of operations but without specific revenue, EPS, or other quantifiable metrics, limiting the market's ability to reassess fundamentals.
  • Continued technical deterioration, with the stock breaking successive support levels over the past three reporting periods.

Technical Analysis

JOBY is trading at $6.71, near the lower end of its recent multi-week range, having decisively broken below the prior $7.50 support established in the August 19 report. This former support now functions as resistance. The consistent five-day (-7.06%) and one-month (-6.15%) declines confirm sustained negative momentum without signs of basing. Absent a catalyst, the next material technical reference points would be prior lows established earlier in the year, given the stock has already lost roughly half its value YTD. The trend structure remains firmly bearish with lower highs and lower lows across all reporting windows.

Bull Case

  • The Resonant Sciences acquisition establishes a dedicated defense business, diversifying Joby's revenue base beyond eVTOL commercialization timing.
  • Resonant has reportedly nearly doubled its technical workforce and advanced key technologies from development into production since 2023, suggesting the acquired business carries operational maturity (PR Newswire).
  • Management's continued pursuit of M&A activity signals ongoing balance sheet capacity to fund inorganic growth despite share price weakness (PR Newswire).
  • The steep cumulative decline (-49.17% YTD) with no identified company-specific negative news for the latest move may indicate oversold conditions relative to fundamentals.
  • Regulatory compliance and disclosure continuity, evidenced by the timely 8-K filing, indicates ongoing operational transparency (SEC EDGAR).

Bear Case

  • Persistent and accelerating downtrend, with the stock down 49.17% YTD, 33.30% over six months, and 10.53% since the last report, reflecting sustained loss of investor confidence.
  • The August 5 8-K filing disclosed no specific revenue, EPS, or financial metrics, leaving investors without concrete data to reassess fundamentals amid the decline.
  • The Resonant Sciences acquisition has undisclosed financial terms and will not close until H1 2027, providing no near-term earnings or cash flow contribution to offset current valuation pressure.
  • Successive breakdowns through key support levels ($8.35 → $7.50 → $6.71) over three consecutive reporting periods indicate deteriorating technical momentum with no signs of stabilization.
  • The absence of a specific negative catalyst behind the latest 10.53% decline suggests broader risk-off sentiment or unaddressed cash flow/dilution concerns are weighing on valuation independent of discrete news events.

CapPilot is AI-powered and can make mistakes. Please double-check responses.

CapPilot leverages generative AI to distill market insights and analysis, as well as answer your questions in chat. While we work hard to ensure accuracy, AI-generated content may occasionally contain inaccuracies or outdated information.

We value your feedback — reporting errors helps us continuously improve.